Loading...

Sinclair Pharma

AIM:SPH
Snowflake Description

Imperfect balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SPH
AIM
£165M
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

Sinclair Pharma plc, a specialty pharmaceutical company, engages in the manufacture, commercialization, and sale of dermatological products worldwide. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Sinclair Pharma has significant price volatility in the past 3 months.
SPH Share Price and Events
7 Day Returns
0%
AIM:SPH
-0.4%
GB Pharmaceuticals
1.4%
GB Market
1 Year Returns
10.1%
AIM:SPH
12.1%
GB Pharmaceuticals
-0.5%
GB Market
SPH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sinclair Pharma (SPH) 0% 0.5% 51.1% 10.1% -19.5% 3%
GB Pharmaceuticals -0.4% -0.1% -3.5% 12.1% 24.4% 50.8%
GB Market 1.4% -2.1% -6.1% -0.5% 34.5% 31%
1 Year Return vs Industry and Market
  • SPH underperformed the Pharmaceuticals industry which returned 12.1% over the past year.
  • SPH outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -0.5% over the past year.
Price Volatility
SPH
Industry
5yr Volatility vs Market

SPH Value

 Is Sinclair Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sinclair Pharma. This is due to cash flow or dividend data being unavailable. The share price is £0.318.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sinclair Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sinclair Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:SPH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in GBP £-0.01
AIM:SPH Share Price ** AIM (2018-11-05) in GBP £0.32
United Kingdom of Great Britain and Northern Ireland Pharmaceuticals Industry PE Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 36.06x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 815 Publicly-Listed Companies 16.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sinclair Pharma.

AIM:SPH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:SPH Share Price ÷ EPS (both in GBP)

= 0.32 ÷ -0.01

-31.85x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sinclair Pharma is loss making, we can't compare its value to the GB Pharmaceuticals industry average.
  • Sinclair Pharma is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Sinclair Pharma's expected growth come at a high price?
Raw Data
AIM:SPH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -31.85x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
41.2%per year
United Kingdom of Great Britain and Northern Ireland Pharmaceuticals Industry PEG Ratio Median Figure of 8 Publicly-Listed Pharmaceuticals Companies 1.76x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 582 Publicly-Listed Companies 1.37x

*Line of best fit is calculated by linear regression .

AIM:SPH PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= -31.85x ÷ 41.2%

-0.77x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sinclair Pharma is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sinclair Pharma's assets?
Raw Data
AIM:SPH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in GBP £0.18
AIM:SPH Share Price * AIM (2018-11-05) in GBP £0.32
United Kingdom of Great Britain and Northern Ireland Pharmaceuticals Industry PB Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 2.12x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,341 Publicly-Listed Companies 1.61x
AIM:SPH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:SPH Share Price ÷ Book Value per Share (both in GBP)

= 0.32 ÷ 0.18

1.8x

* Primary Listing of Sinclair Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sinclair Pharma is good value based on assets compared to the GB Pharmaceuticals industry average.
X
Value checks
We assess Sinclair Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Sinclair Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SPH Future Performance

 How is Sinclair Pharma expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sinclair Pharma expected to grow at an attractive rate?
  • Unable to compare Sinclair Pharma's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Sinclair Pharma's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as it is expected to be loss making during the next 1-3 years.
  • Sinclair Pharma's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
AIM:SPH Future Growth Rates Data Sources
Data Point Source Value (per year)
AIM:SPH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 41.2%
AIM:SPH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 24.8%
United Kingdom of Great Britain and Northern Ireland Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 23.7%
United Kingdom of Great Britain and Northern Ireland Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 6.4%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 11%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 4.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:SPH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:SPH Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 68 -3 2
2018-12-31 54 -7 2
AIM:SPH Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-06-30 47 -9 -5
2018-03-31 46 -10 -3
2017-12-31 45 -11 -1
2017-06-30 33 -14 -27
2017-03-31 32 -14 -24
2016-12-31 30 -13 -22
2015-12-31 73 1 -12
2015-09-30 74 3 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sinclair Pharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Sinclair Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:SPH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Sinclair Pharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:SPH Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31
2018-12-31
AIM:SPH Past Financials Data
Date (Data in GBP Millions) EPS *
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.00
2017-06-30 -0.05
2017-03-31 -0.05
2016-12-31 -0.04
2015-12-31 -0.02
2015-09-30 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sinclair Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sinclair Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sinclair Pharma has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SPH Past Performance

  How has Sinclair Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sinclair Pharma's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sinclair Pharma does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Sinclair Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sinclair Pharma's 1-year growth to the GB Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Sinclair Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sinclair Pharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:SPH Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 46.50 -5.03 39.38
2018-03-31 45.90 -2.85 39.22
2017-12-31 45.30 -0.67 39.06
2017-06-30 33.13 -26.64 39.71
2017-03-31 31.73 -24.45 38.73
2016-12-31 30.33 -22.26 37.74
2015-12-31 73.01 -12.14 42.81
2015-09-30 74.45 -9.67 42.28
2015-06-30 27.84 -23.37 29.77
2015-03-31 38.74 -21.31 32.15
2014-12-31 49.64 -19.25 34.54
2014-09-30 56.60 -11.67 34.13
2014-06-30 63.56 -4.09 33.71
2013-12-31 56.89 -13.02 31.18
2013-09-30 56.13 -14.44 31.37
2013-06-30 55.38 -15.85 31.55
2012-12-31 50.98 -5.08 31.84
2012-09-30 51.20 -5.09 31.65
2012-06-30 51.42 -5.10 31.46
2012-03-31 46.83 -10.95 30.06
2011-12-31 42.25 -13.25 28.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sinclair Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sinclair Pharma has efficiently used its assets last year compared to the GB Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sinclair Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sinclair Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sinclair Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SPH Health

 How is Sinclair Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sinclair Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sinclair Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sinclair Pharma's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Sinclair Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sinclair Pharma Company Filings, last reported 4 months ago.

AIM:SPH Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 88.80 18.17 3.38
2018-03-31 88.80 18.17 3.38
2017-12-31 99.18 4.80 1.84
2017-06-30 92.88 2.41 3.16
2017-03-31 92.88 2.41 3.16
2016-12-31 100.32 0.00 16.77
2015-12-31 104.62 0.00 75.38
2015-09-30 104.62 0.00 75.38
2015-06-30 105.57 51.80 12.66
2015-03-31 105.57 51.80 12.66
2014-12-31 111.40 54.38 13.43
2014-09-30 111.40 54.38 13.43
2014-06-30 117.92 54.56 17.53
2013-12-31 102.54 9.87 0.81
2013-09-30 102.54 9.87 0.81
2013-06-30 110.54 11.92 5.06
2012-12-31 117.80 11.54 2.88
2012-09-30 117.80 11.54 2.88
2012-06-30 114.28 13.10 4.04
2012-03-31 114.28 13.10 4.04
2011-12-31 119.37 14.93 4.43
  • Sinclair Pharma's level of debt (20.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (10.8% vs 20.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sinclair Pharma has less than a year of cash runway based on current free cash flow.
  • Sinclair Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 71.6% each year.
X
Financial health checks
We assess Sinclair Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sinclair Pharma has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SPH Dividends

 What is Sinclair Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sinclair Pharma dividends. Estimated to be 0% next year.
If you bought £2,000 of Sinclair Pharma shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sinclair Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sinclair Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:SPH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 6 Stocks 4.3%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 701 Stocks 4.1%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 1.9%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:SPH Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sinclair Pharma has not reported any payouts.
  • Unable to verify if Sinclair Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sinclair Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sinclair Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Sinclair Pharma's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess Sinclair Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sinclair Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sinclair Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SPH Management

 What is the CEO of Sinclair Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Spooner
COMPENSATION £587,000
TENURE AS CEO 9.1 years
CEO Bio

Mr. Christopher P. Spooner, also known as Chris, has been the Chief Executive Officer at Sinclair Pharma plc since October 2009. Mr. Spooner Founded HealthCor Management U.K. and served as its Chief Executive Officer. Mr. Spooner joined Sinclair following a career in financial services. He enjoyed a career as the senior pharmaceuticals analyst at various investment banks covering the European healthcare sector. He has been a Director of Sinclair Pharma plc since December 22, 2009. Mr. Spooner holds an M.A. in Economics from King’s College, Cambridge University.

CEO Compensation
  • Chris's compensation has been consistent with company performance over the past year.
  • Chris's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Sinclair Pharma management team in years:

6.4
Average Tenure
47
Average Age
  • The average tenure for the Sinclair Pharma management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Chris Spooner

TITLE
CEO & Executive Director
COMPENSATION
£587K
TENURE
9.1 yrs

Alan Olby

TITLE
CFO & Director
COMPENSATION
£320K
AGE
47
TENURE
8.9 yrs

Jayne Burrell

TITLE
Group General Counsel & Company Secretary
AGE
43
TENURE
3.8 yrs

Emilie Croissant

TITLE
Head of Europe & Global Marketing

Nairn McMaster

TITLE
Head of Latin America

Louis Payet

TITLE
Head of Business Development
TENURE
2.1 yrs

Doug Abel

TITLE
Head of North America
AGE
56

Emma Rothery

TITLE
Commercial Head of Operations - United Kingdom & NI
TENURE
1.8 yrs

Kamal Abbasi

TITLE
Head of APAC

Jean-Louis Lamandé

TITLE
Operations Finance Director
TENURE
8.9 yrs
Board of Directors Tenure

Average tenure and age of the Sinclair Pharma board of directors in years:

6.5
Average Tenure
52
Average Age
  • The tenure for the Sinclair Pharma board of directors is about average.
Board of Directors

Grahame Cook

TITLE
Non Executive Chairman
COMPENSATION
£75K
AGE
59
TENURE
9.9 yrs

Chris Spooner

TITLE
CEO & Executive Director
COMPENSATION
£587K
TENURE
8.9 yrs

Alan Olby

TITLE
CFO & Director
COMPENSATION
£320K
AGE
47
TENURE
2.3 yrs

Jeff Thompson

TITLE
Non-Executive Director
COMPENSATION
£45K
AGE
52
TENURE
4.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Max Price (£) Value (£)
05. Nov 18 Buy Tibra Trading Europe Ltd., Asset Management Arm Company 02. Nov 18 02. Nov 18 495 £0.32 £157.41
02. Nov 18 Buy Tibra Trading Europe Ltd., Asset Management Arm Company 01. Nov 18 01. Nov 18 182,852 £0.32 £58,329.80
01. Nov 18 Buy Tibra Trading Europe Ltd., Asset Management Arm Company 31. Oct 18 31. Oct 18 2,051,867 £0.32 £654,442.26
29. Oct 18 Buy Tibra Trading Europe Ltd., Asset Management Arm Company 26. Oct 18 26. Oct 18 343,463 £0.32 £109,221.14
18. Oct 18 Buy LMR Partners LLP Company 17. Oct 18 17. Oct 18 10,000,000 £0.32 £3,150,002.15
26. Oct 18 Buy Tibra Trading Europe Ltd., Asset Management Arm Company 25. Oct 18 25. Oct 18 743,503 £0.32 £236,434.06
26. Oct 18 Buy Gwm Asset Management Ltd. Company 25. Oct 18 25. Oct 18 1,000,000 £0.32 £318,000.14
25. Oct 18 Buy Tibra Trading Europe Ltd., Asset Management Arm Company 24. Oct 18 24. Oct 18 1,836,819 £0.32 £584,047.25
24. Oct 18 Buy Tavira Securities Limited, Asset Management Arm Company 23. Oct 18 23. Oct 18 700,000 £0.32 £220,499.91
17. Oct 18 Buy Syquant Capital SAS Company 16. Oct 18 16. Oct 18 7,000,000 £0.32 £2,205,000.68
19. Oct 18 Buy Tavira Securities Limited, Asset Management Arm Company 18. Oct 18 18. Oct 18 11,150,000 £0.32 £3,523,397.38
18. Oct 18 Sell Toscafund Asset Management LLP Company 17. Oct 18 17. Oct 18 -56,613,603 £0.32 £-17,833,297.14
17. Oct 18 Sell Soros Fund Management LLC Company 16. Oct 18 16. Oct 18 -10,000,000 £0.32 £-3,150,000.98
17. Oct 18 Sell Toscafund Asset Management LLP Company 16. Oct 18 16. Oct 18 -92,000,000 £0.32 £-28,980,008.99
17. Oct 18 Buy BNP Paribas, Private & Investment Banking Investments Company 16. Oct 18 16. Oct 18 25,000,000 £0.32 £7,880,000.29
10. Oct 18 Sell Soros Fund Management LLC Company 09. Oct 18 09. Oct 18 -1,750,000 £0.32 £-553,000.59
09. Oct 18 Sell Soros Fund Management LLC Company 08. Oct 18 08. Oct 18 -1,000,000 £0.32 £-316,000.04
09. Oct 18 Buy Oddo Bhf Asset Management SAS Company 08. Oct 18 08. Oct 18 5,516,268 £0.32 £1,743,140.93
03. Oct 18 Buy Oddo Bhf Asset Management SAS Company 02. Oct 18 02. Oct 18 2,083,732 £0.31 £654,124.67
28. Sep 18 Buy BNP Paribas, Private & Investment Banking Investments Company 27. Sep 18 27. Sep 18 750,000 £0.31 £233,699.76
27. Sep 18 Buy Cigogne Management S.A. Company 26. Sep 18 26. Sep 18 1,700,000 £0.31 £530,740.30
27. Sep 18 Sell Soros Fund Management LLC Company 26. Sep 18 26. Sep 18 -1,000,000 £0.31 £-311,000.09
26. Sep 18 Sell Soros Fund Management LLC Company 25. Sep 18 25. Sep 18 -500,000 £0.31 £-155,500.01
24. Sep 18 Sell Soros Fund Management LLC Company 21. Sep 18 21. Sep 18 -500,000 £0.31 £-155,250.19
21. Sep 18 Sell Robert Swanson Individual 11. Sep 18 18. Sep 18 -13,267,172 £0.31 £-4,020,029.36
21. Sep 18 Sell Soros Fund Management LLC Company 20. Sep 18 20. Sep 18 -2,000,000 £0.31 £-619,999.56
21. Sep 18 Buy BNP Paribas, Private & Investment Banking Investments Company 20. Sep 18 20. Sep 18 2,000,000 £0.31 £621,199.30
20. Sep 18 Buy BNP Paribas, Private & Investment Banking Investments Company 19. Sep 18 19. Sep 18 250,000 £0.31 £76,899.99
20. Sep 18 Sell Soros Fund Management LLC Company 19. Sep 18 19. Sep 18 -1,000,000 £0.31 £-307,999.97
19. Sep 18 Buy Oddo Bhf Asset Management SAS Company 18. Sep 18 18. Sep 18 17,400,000 £0.31 £5,341,796.49
19. Sep 18 Sell Schroder Investment Management Limited Company 18. Sep 18 18. Sep 18 -16,931,971 £0.31 £-5,198,111.68
18. Sep 18 Buy BNP Paribas, Private & Investment Banking Investments Company 17. Sep 18 17. Sep 18 1,200,000 £0.29 £352,919.83
18. Sep 18 Buy Cigogne Management S.A. Company 17. Sep 18 17. Sep 18 65,815 £0.29 £19,224.56
12. Sep 18 Buy Cigogne Management S.A. Company 11. Sep 18 11. Sep 18 1,000,000 £0.30 £303,299.68
11. Sep 18 Buy Cigogne Management S.A. Company 10. Sep 18 10. Sep 18 1,250,000 £0.28 £350,125.18
12. Sep 18 Sell Mirabaud Asset Management Limited Company 11. Sep 18 11. Sep 18 -10,582,196 £0.30 £-3,206,409.17
10. Jul 18 Buy Toscafund Asset Management LLP Company 09. Jul 18 09. Jul 18 500,000 £0.22 £111,725.10
06. Jul 18 Sell Schroder Investment Management Limited Company 05. Jul 18 05. Jul 18 -250,000 £0.19 £-47,574.97
16. Jan 18 Buy Christopher Spooner Individual 16. Jan 18 16. Jan 18 200,000 £0.23 £46,300.05
17. Jan 18 Buy Jeffrey Thompson Individual 16. Jan 18 16. Jan 18 200,000 £0.23 £46,199.93
X
Management checks
We assess Sinclair Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sinclair Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SPH News

External News
Loading...
Simply Wall St News

Sinclair Pharma plc (LON:SPH) Is Trading At A 48.11% Discount

In this article I am going to calculate the intrinsic value of Sinclair Pharma plc (LON:SPH). … by projecting its future cash flows and then discounting them to today's value. … Discounted Cash Flows (DCF).

Simply Wall St -

Is Sinclair Pharma plc's (LON:SPH) CEO Overpaid Relative To Its Peers?

Performance can be measured based on factors such as earnings and total shareholder return (TSR). … I believe earnings is a cleaner proxy, since many factors can impact share price, and therefore, TSR. … Usually I would look at market cap and earnings as a proxy for performance, however, SPH's negative earnings lower the effectiveness of this method.

Simply Wall St -

Sinclair Pharma plc (LON:SPH): Time For A Financial Health Check

Over the past year, SPH has borrowed debt capital of around UK£4.80M made up of current and long term debt. … With this growth in debt, SPH currently has UK£1.84M remaining in cash and short-term investments for investing into the business. … SPH’s level of debt is low relative to its total equity, at 4.84%.

Simply Wall St -

Should You Buy Sinclair Pharma plc (LON:SPH)?

A question to answer is whether Sinclair Pharma's current trading price of £0.18 reflective of the actual value of the small-cap? … Let’s take a look at Sinclair Pharma’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. … What’s more interesting is that, Sinclair Pharma’s share price is quite stable, which could mean two things: firstly, it may take the share price a while to move to its intrinsic value, and secondly, there may be less chances to buy low in the future once it reaches that value.

Simply Wall St -

What Do These Insiders Know That You Don't?

Sinclair Pharma plc (AIM:SPH) is one of United Kingdom’s small-cap stocks that saw some insider buying over the past three months, with insiders investing in 400,000 shares during this period. … Vectura Group plc's (LSE:VEC) insiders have invested 124,033 shares in the small-cap stocks within the past three months. … Countrywide plc (LSE:CWD) is one of United Kingdom’s small-cap stocks that saw some insider buying over the past three months, with insiders investing in 400,000 shares during this period.

Simply Wall St -

Did Insiders Buy On Sinclair Pharma plc's (LON:SPH) Price Volatility?

Sinclair Pharma plc, a specialty pharmaceutical company, engages in the manufacture, commercialization, and sale of dermatological products worldwide. … AIM:SPH Future Profit Apr 13th 18 On the surface, analysts’ revenue growth projection of 133.35% over the next three years provides a very optimistic outlook for the business which is consistent with the signal company insiders are sending with their net buying activity. … Next Steps: Sinclair Pharma’s net buying tells us the stock is in favour with some insiders, which is consistent with the significant expected earnings growth, on top of a reasonable share price movement around the same time.

Simply Wall St -

Should You Be Holding Sinclair Pharma plc (LON:SPH) Right Now?

Sinclair Pharma's beta of 0.05 indicates that the stock value will be less variable compared to the whole stock market. … Based on this beta value, SPH appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.

Simply Wall St -

With A -55.08% Earnings Drop, Did Sinclair Pharma plc (LON:SPH) Really Underperform?

Understanding Sinclair Pharma plc's (AIM:SPH) performance as a company requires examining more than earnings from one point in time. … Today I will take you through a basic sense check to gain perspective on how Sinclair Pharma is doing by evaluating its latest earnings with its longer term trend as well as its industry peers' performance over the same period. … Check out our latest analysis for Sinclair Pharma Commentary On SPH's Past Performance For the purpose of this commentary, I like to use the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data.

Simply Wall St -

Sinclair Pharma plc's (LON:SPH) Path To Profitability

In this article, I will touch on the expectations for SPH’s growth and when analysts expect the company to become profitable. … AIM:SPH Past Future Earnings Mar 5th 18 Given this is a high-level overview, I won’t go into detail the detail of SPH’s upcoming projects, but, bear in mind that by and large a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. … This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

Simply Wall St -

Top AIM Growth Stocks To Buy

SPH’s projected future profit growth is an exceptional 52.50%, with an underlying 93.51% growth from its revenues expected over the upcoming years. … STCM’s projected future profit growth is a robust 23.65%, with an underlying 36.06% growth from its revenues expected over the upcoming years. … CVSG’s projected future profit growth is a robust 20.75%, with an underlying 17.58% growth from its revenues expected over the upcoming years.

Simply Wall St -

SPH Company Info

Map
Description

Sinclair Pharma plc, a specialty pharmaceutical company, engages in the manufacture, commercialization, and sale of dermatological products worldwide. It provides Silhouette Soft, a resorbable poly-L-lactic acid(PLLA)/PLGA suture with bi-directional resorbable cones for skin repositioning and tightening; and Ellansé, which offers dermal fillers. The company also provides Perfectha for wrinkle correction, facial contouring, and volume restoration; and Sculptra designed to stimulate collagen growth. It serves healthcare providers and plastic surgeons. The company was formerly known as Sinclair IS Pharma plc and changed its name to Sinclair Pharma plc in December 2015. Sinclair Pharma plc was founded in 1971 and is headquartered in London, the United Kingdom.

Details
Name: Sinclair Pharma plc
SPH
Exchange: AIM
Founded: 1971
£164,614,952
517,657,084
Website: http://www.sinclairispharma.com
Address: Sinclair Pharma plc
Whitfield Court,
1st Floor,
London,
Greater London, W1T 2RQ,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM SPH Ordinary Shares London Stock Exchange AIM Market GB GBP 11. Dec 2003
OTCPK SCLR.F Ordinary Shares Pink Sheets LLC US USD 11. Dec 2003
DB SVB Ordinary Shares Deutsche Boerse AG DE EUR 11. Dec 2003
Number of employees
Current staff
Staff numbers
195
Sinclair Pharma employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/11/06 18:18
End of day share price update: 2018/11/05 00:00
Last estimates confirmation: 2018/08/29
Last earnings filing: 2018/09/27
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.